Olinciguat

The Soluble Guanylate Cyclase Stimulator Olinciguat Attenuates Leukocyte/Endothelial Cell Interactions in Berkeley SCD Mice

24th European Hematology Association (EHA) Congress (2019)

Huihui Li, Sung-Kyun Lee, Boris Tchernychev, Regina. M. Graul, Jaime Masferrer, Paul Frenette

In this preclinical study, olinciguat – either alone or in combination with the approved sickle cell treatment hydroxyurea – improved blood flow and reduced leukocyte/endothelial cell interactions. In patients with sickle cell disease, these leukocyte/endothelial cell interactions can block small blood vessels, interrupting normal blood flow and oxygen delivery and causing complications such as vaso-occlusive crises, organ damage, and daily symptoms.

Olinciguat and a combination of olinciguat and hydroxyurea significantly attenuated leukocyte adhesion in a mouse model of sickle cell disease

Adhesion efficiency represents the number of adherent leukocytes per 100um of video image divided by number of rolling leukocytes passing each vessel per minute; ***p<.001 vs vehicle Li et al. (EHA 2019) poster presentation

Preclinical study in a sickle cell disease model evaluating olinciguat’s effect on blood flow and clogged blood vessels

Boris Tchernychev, principal investigator at Cyclerion, shares more about preclinical research that evaluated whether olinciguat could reduce leukocyte/endothelial cell interactions in a preclinical mouse model of sickle cell disease. In patients with sickle cell disease, leukocyte/endothelial cell interactions frequently occur on the vascular wall, forming clumps of cells within the blood vessels that can interrupt normal blood flow and oxygen delivery and cause complications such as painful crises, organ damage, and daily symptoms.

Return to Archive
Top